<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4306">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265394</url>
  </required_header>
  <id_info>
    <org_study_id>GE-067-015</org_study_id>
    <nct_id>NCT01265394</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects</brief_title>
  <official_title>A Single-arm, Open-label, Multi-center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>i3 Statprobe</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyloid is an abnormal chemical found in the brain of patients with Alzheimer's Disease
      (AD). The study drug helps produce pictures of amyloid in the brain. The purpose of this
      study is to determine how well the study drug performs in young healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid</measure>
    <time_frame>PET scans performed on patients 90 minutes post Flutemetmol Administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>The visual assessment of Flutemetamol PET image was performed by independent readers trained in the evaluation of PET brain amyloid imaging.
The measure would consisted of the number of brain scans with amyloid (abnormal reading) or without amyloid (normal reading).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Amyloid Content in Different Parts of the Brain</measure>
    <time_frame>PET scans performed on patients 90 minutes post Flutemetmol Administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Is the computerized measurement of amyloid content in different parts of the brain.
The Standard Uptake Value Ratio (SUVR) is defined as an average of frontal, anterior cingulate, pariteal, lateral-temporal and posterior cingulate / precuneous uptake following administration of Flutemetamol F18 Injection.
The Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions.
The Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions. Both regions of the brain will provide the SUVR measurements.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>(18F) Flutemetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F] Flutemetamol</intervention_name>
    <description>Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.</description>
    <arm_group_label>(18F) Flutemetamol</arm_group_label>
    <other_name>AH110690</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject age is 18 to 40 years.

          -  The subject has no evidence of thinking or memory problems by medical history.

          -  The subject has a normal MRI scan.

          -  The subject's general health is adequate to comply with study procedures.

          -  The subject is willing and able to participate in all study procedures.

        Exclusion Criteria:

          -  The subject has received any medical ionizing radiation exposure in the last 12
             months (except planar x-ray or head CT).

          -  The subject has a contraindication for (cannot undergo) MRI.

          -  The subject has a history of head injury with loss of consciousness.

          -  The subject has any significant medical, psychiatric or neurological condition that
             might be associated with brain pathology.

          -  The subject has a family history of Alzheimer's Disease (AD); more than 1
             first-degree relative.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sherwin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>GE Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GE Healthcare</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 21, 2013</lastchanged_date>
  <firstreceived_date>December 21, 2010</firstreceived_date>
  <firstreceived_results_date>March 27, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyloid</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Standard uptake value ratios</keyword>
  <keyword>Healthy Subjects</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>(18F) Flutemetamol</title>
          <description>[18F] Flutemetamol : Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subjects withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is the number of participants that completed.</population>
      <group_list>
        <group group_id="B1">
          <title>(18F) Flutemetamol</title>
          <description>[18F] Flutemetamol : Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="181"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="181"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29" spread="5.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="103"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="78"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="127"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Belgium</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Finland</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid</title>
        <description>The visual assessment of Flutemetamol PET image was performed by independent readers trained in the evaluation of PET brain amyloid imaging.
The measure would consisted of the number of brain scans with amyloid (abnormal reading) or without amyloid (normal reading).</description>
        <time_frame>PET scans performed on patients 90 minutes post Flutemetmol Administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Healthy young adult subjects aged 18 to 40 are presumed to be amyloid negative</population>
        <group_list>
          <group group_id="O1">
            <title>Normal and Abnormal Reads With or Without Amyloid</title>
            <description>Each Subject received a dose of [18F] Flutemetamol : Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="181"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid</title>
            <description>The visual assessment of Flutemetamol PET image was performed by independent readers trained in the evaluation of PET brain amyloid imaging.
The measure would consisted of the number of brain scans with amyloid (abnormal reading) or without amyloid (normal reading).</description>
            <units>Brain Scans Read</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Reader 1 -Normal Read-no amyloid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="181" lower_limit="98.0" upper_limit="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 1- Abnormal Read- amyloid is present</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="60.6" upper_limit="74.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2 - Normal Read-no amyloid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="123" lower_limit="97.0" upper_limit="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2 - Abnormal Read-amyloid is present</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58" lower_limit="97.0" upper_limit="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3 - Normal Read-no amyloid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="180" lower_limit="96.1" upper_limit="99.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3 - Abnormal Read-amyloid is present</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 4 - Normal Read-no amyloid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="180"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 4 - Abnormal Read-amyloid is present</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 5 - Normal Read-no amyloid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="179"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 5 - Abnormal Read-amyloid is present</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Amyloid Content in Different Parts of the Brain</title>
        <description>Is the computerized measurement of amyloid content in different parts of the brain.
The Standard Uptake Value Ratio (SUVR) is defined as an average of frontal, anterior cingulate, pariteal, lateral-temporal and posterior cingulate / precuneous uptake following administration of Flutemetamol F18 Injection.
The Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions.
The Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions. Both regions of the brain will provide the SUVR measurements.</description>
        <time_frame>PET scans performed on patients 90 minutes post Flutemetmol Administration</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions. Both regions of the brain will provide the SUVR measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>(18F) Flutemetamol Injection</title>
            <description>Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="181"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Measurement of Amyloid Content in Different Parts of the Brain</title>
            <description>Is the computerized measurement of amyloid content in different parts of the brain.
The Standard Uptake Value Ratio (SUVR) is defined as an average of frontal, anterior cingulate, pariteal, lateral-temporal and posterior cingulate / precuneous uptake following administration of Flutemetamol F18 Injection.
The Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions.
The Standard Uptake Value Ratio is calculated for two regions of the brain, the Cerebullum and the Pons regions. Both regions of the brain will provide the SUVR measurements.</description>
            <units>Standard Uptake Value Ratio ( SUVR)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Cerebullum Region</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.12" spread="0.097" lower_limit="1.108" upper_limit="1.136"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pons Region</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.49" spread="0.036" lower_limit="0.487" upper_limit="0.498"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>(18F) Flutemetamol</title>
          <description>[18F] Flutemetamol : Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders and Administration Site Conditions</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular System Disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Vascular System Disorders-Flushing</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul Sherwin</name_or_title>
      <organization>GE Healthcare</organization>
      <phone>1-609-514-6820</phone>
      <email>paulsherwin@ge.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
